QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:PLSE

Pulse Biosciences (PLSE) Stock Price, News & Analysis

$9.12
-0.33 (-3.49%)
(As of 02/23/2024 ET)
Today's Range
$9.06
$9.56
50-Day Range
$7.80
$12.84
52-Week Range
$2.36
$13.62
Volume
135,399 shs
Average Volume
190,813 shs
Market Capitalization
$502.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Pulse Biosciences MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
16.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$5.49 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.71 out of 5 stars

Medical Sector

845th out of 939 stocks

Surgical & Medical Instruments Industry

92nd out of 93 stocks


PLSE stock logo

About Pulse Biosciences Stock (NASDAQ:PLSE)

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.

PLSE Stock Price History

PLSE Stock News Headlines

Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
Gold is SOARING – here's what you need to do
Everything is lining up perfectly for a historic gold bull run. One gold expert says he's found the best way to get in, for just $5.
Pulse Biosciences Files 510(k) Submission With FDA For Its CellFX NsPFA
Q3 2023 Pulse Biosciences Inc Earnings Call
Pulse Biosciences GAAP EPS of -$0.19
Pulse Biosciences, Inc. (PLSE) Q3 Loss Drops
See More Headlines
Receive PLSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/30/2023
Today
2/23/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PLSE
Fax
N/A
Employees
61
Year Founded
N/A

Profitability

Net Income
$-58,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$700,000.00
Book Value
($0.06) per share

Miscellaneous

Free Float
16,690,000
Market Cap
$499.02 million
Optionable
Optionable
Beta
1.72
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Robert W. Duggan (Age 79)
    Executive Chairman
  • Mr. Kevin P. Danahy (Age 53)
    President & CEO
    Comp: $393.25k
  • Mr. Darrin R. Uecker (Age 58)
    CTO & Director
    Comp: $487.24k
  • Mr. Mitchell E. Levinson (Age 64)
    Chief Strategy Officer
    Comp: $361.34k
  • Dr. Richard Nuccitelli Ph.D.
    Chief Science Officer
  • Mr. Kenneth B. Stratton Esq. (Age 55)
    J.D., General Counsel & Corporate Secretary
  • Ms. Patty Perla
    Vice President of Human Resources
  • Mr. David Danitz
    Senior Vice President of Engineering
  • Dr. Gansevoort Dunnington M.D.
    Chief Medical Officer
  • Dr. Niv Ad M.D.
    Chief Science Officer of Cardiac Surgery














PLSE Stock Analysis - Frequently Asked Questions

How have PLSE shares performed in 2024?

Pulse Biosciences' stock was trading at $12.24 on January 1st, 2024. Since then, PLSE shares have decreased by 25.5% and is now trading at $9.12.
View the best growth stocks for 2024 here
.

Are investors shorting Pulse Biosciences?

Pulse Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 2,630,000 shares, an increase of 6.5% from the January 15th total of 2,470,000 shares. Based on an average daily trading volume, of 293,800 shares, the short-interest ratio is currently 9.0 days. Approximately 16.3% of the company's stock are short sold.
View Pulse Biosciences' Short Interest
.

When is Pulse Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our PLSE earnings forecast
.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) posted its quarterly earnings results on Thursday, March, 30th. The company reported ($0.24) EPS for the quarter. The firm had revenue of ($0.01) million for the quarter.

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX).

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.19%), Griffin Asset Management Inc. (0.47%), Northern Trust Corp (0.33%), Westside Investment Management Inc. (0.06%), Nuveen Asset Management LLC (0.05%) and Barclays PLC (0.04%). Insiders that own company stock include Kevin Patrick Danahy, Mitchell E Levinson and Robert W Duggan.
View institutional ownership trends
.

How do I buy shares of Pulse Biosciences?

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PLSE) was last updated on 2/23/2024 by MarketBeat.com Staff